Louvain-la-Neuve, Belgium, November 13, 2015 - IBA (Ion Beam Applications S.A.), the world’s leading provider of proton therapy solutions for the treatment of cancer, has signed contracts with Proton Partners International (PPI) to install three Proteus®ONE compact proton therapy systems in private clinics in the United Kingdom: one in Newport (Wales), one in Newcastle (England) and a third location to be identified at a later stage.
The contracts, which were previously announced upon the signing of a letter of intent in an IBA press release dated June 25th 2015, will also include a long-term service agreement. The typical end-user price for a Proteus®ONE system with this service contract ranges between EUR 35 and 40 million.
These three projects are part of a framework agreement that IBA and Philips signed in September 2014 to advance the diagnosis and treatment of cancer and demonstrate the efficiency and potential of the collaboration between the two organizations.
Ad Statistics
Times Displayed: 21862
Times Visited: 433 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money
Olivier Legrain, Chief Executive Officer of IBA, commented: “Proton Partners International’s selection of IBA not only strengthens our world leading position in proton therapy, but also demonstrates the preference of IBA as the most experienced proton therapy provider in the market with the fastest delivery times. These contracts also demonstrate the potential of our collaboration with Philips as we look to bring cutting edge proton therapy to new regions.”
Mike Moran, Chief Executive Officer of Proton Partners International Limited, added: "We are delighted to announce that we will be working with IBA, the world leader in proton therapy technology, who will equip our centres to the highest specifications. We are excited about the opportunity to deliver the first proton therapy centres in the UK and we look forward to working with a range of stakeholders to help support the research effort in the wider use of proton beam therapy for the benefit of the patients from all over UK."
Neil Mesher, Managing Director, Health Systems, Philips UK, added: “These new centers represent a major step forward in the delivery of care for oncology patients in the UK. We are delighted to be working with Proton Partners International and IBA which is strongly in line with our aim of improving people’s lives through meaningful innovation.”
